IMC-F106C Combinations for Solid Cancers

This trial tests a new treatment called brenetafusp (also known as IMC-F106C), designed to help the immune system attack certain solid cancers. Researchers aim to assess the safety and effectiveness of brenetafusp, either alone or combined with other treatments like chemotherapy or immune therapies. This trial might suit individuals with PRAME-positive cancer and an HLA-A2 marker, especially if standard treatments have not succeeded. As a Phase 1, Phase 2 trial, participants have the opportunity to be among the first to receive this new treatment and help evaluate its effectiveness in a smaller group.

The trial does not specify if you must stop taking your current medications, but it mentions that there should be an adequate washout period (time without taking certain medications) from prior anticancer therapy. It's best to discuss your current medications with the trial team.

Research has shown that brenetafusp (IMC-F106C) is generally safe for humans. In earlier studies, this treatment effectively activated T cells, which then moved into tumors, aiding the immune system in fighting cancer cells. These studies also found that brenetafusp is well-tolerated, with no major safety issues.

For those considering brenetafusp with other treatments, it remains safe when combined with anti-PD(L)1 drugs like pembrolizumab. It is also well-tolerated when used with chemotherapy or targeted therapies.

Researchers are excited about brenetafusp because it offers a fresh approach to treating solid cancers. Unlike traditional therapies that often rely on standard chemotherapy or broad-spectrum immunotherapies, brenetafusp is designed to target specific proteins involved in cancer growth. This precision allows for a more tailored treatment, potentially leading to better outcomes with fewer side effects. Furthermore, the combination of brenetafusp with other agents like pembrolizumab or targeted therapies can enhance its effectiveness, offering hope for improved response rates in patients who might not benefit from current standard treatments.

Research has shown that brenetafusp, also known as IMC-F106C, may help treat solid cancers with the PRAME antigen. Studies have found that it activates T cells, which then move into tumors, a positive sign for fighting cancer. Patients using brenetafusp have experienced lasting benefits, including partial improvements in cancers like melanoma and ovarian cancer. In this trial, participants may receive brenetafusp alone or with other treatments. For example, one arm involves brenetafusp with anti-PD1 drugs, while other arms combine it with chemotherapy or targeted therapies. Brenetafusp remains effective and is generally well-tolerated across these combinations. These findings suggest that brenetafusp could be a promising treatment option for people with certain solid tumors.¹²³⁴⁶